Acting CEO Masoud Khayyami comments on the report for the second quarter
Discover the highlights of SpectraCure’s 2024 half year report! Listen when Dr. Masoud Khayyami, former CEO of SpectraCure, comments on the report for the second quarter, with Erika Eliasson Ekberger as moderator. The report can be found here (in Swedish). https://youtu.be/ELQ6In9finM
Interview with Jonathan S Fainberg, MD
One of the co-investigators of the Prostate Cancer Recurrence Clinical Trial at Memorial Sloan Kettering Cancer Center (MSKCC) is Jonathan Fainberg, MD, MPH, who specializes in localized prostate cancer, focal therapy, and partial ablation, which are methods of precisely treating intermediate-risk prostate cancer. Fainberg will give you insight into prostate cancer, today’s treatments and what […]
Masoud Khayyami comments on the report for the fourth quarter
Listen as Masoud Khayyami, Acting CEO of SpectraCure, discusses milestones and events from the fourth quarter, with Erika Eliasson Ekberger as the moderator. The report for the fourth quarter of 2023 can be found here: https://storage.mfn.se/8cdb4261-1010-4df7-aea0-1ef1056e46bb/spectracure-ab-publ-bokslutskommunike-for-januari-december-2023.pdf https://spcmainstg.wpengine.com/wp-content/uploads/2024/02/Tf.-VD-Masoud-Khayyami-kommenterar-det-fjarde-kvartalet-for-2023-1.mp4
Interview with Tomas Kramar, SpectraCure’s board member!
With over 40 years of experience in the industry, including prominent roles as CEO of Siemens Healthineers and CEO of Siemens Healthcare Diagnostics, Tomas Kramar has an impressive career in life science. His decision to join SpectraCure’s board reflects his belief that the company has the potential to offer an exciting and promising solution for […]
Masoud Khayyami presents SpectraCure at investor meetingon December 5 in Lund!
Masoud Khayyami, acting CEO of SpectraCure, will present the company at an investor meeting organized by Cardeon in Lund on December 5th. For further information regarding the event schedule and registration, please visit: https://storage.mfn.se/dd21b2ac-5a14-4b98-addb-0b17de29e758/kapitaldag-info-och-schema.pdf
Full speed ahead at Medica
Johannes Swartling, CTO, and Marcelo Soto Thompson, RnD specialist, have been on-site at Medica/Compamed in Düsseldorf this week, the world’s largest trade fair for medical technology and a central meeting place for companies and decision-makers in the medical technology industry. SpectraCure is collaborating with the MedPhab Pilot Line to showcase the ongoing industrialisation project. Also […]
Meet SpectraCure’s board member, Homer Pien!
Homer Pien has an impressive background with experience in leading positions at organisations such as Philips, Massachusetts General Hospital, Harvard Medical School, and several start-up companies. He has chosen to engage with SpectraCure’s board because he believes there is a significant need for individualised prostate cancer treatments. The way SpectraCure conducts prostate cancer treatment with […]
Visit at LASER World of PHOTONICS
Johannes Swartling, SpectraCures CTO, visited LASER World of PHOTONICS in Munich this week to meet suppliers in the photonics industry and attend the presentation of SpectraCure’s industrial doctoral student, Stefan Susnjar, who showcased his master’s thesis. Also present at the event was the European education network PHAST, of which SpectraCure is a part. LASER World […]
SpectraCure’s CTO, Johannes Swartling, shares knowledge about photodynamic therapy at PHAST meeting
SpectraCure is part of the European training network PHAST (Photonics for Healthcare: multiscale cancer diagnosiS and Therapy), which educates and trains young researchers in biophotonics to promote innovations in cancer diagnosis and treatment. PHAST is funded by the EU’s research-support framework program, Horizon 2020. In PHAST, about fifteen PhD students are linked to universities and […]
SpectraCure is noticed by Skånska dagbladet
Under the category “Spiritual companies in Lund”, Skånska Dagbladet has drawn attention to SpectraCure! In an article, Johannes Swartling, CTO, is interviewed, where he tells us more about the company, our method and the ongoing clinical study. The article can be read here: https://www.skd.se/2023-03-19/solida-tumorer-kan-botas-med-lundametod
